新辅助免疫治疗对非小细胞肺癌手术诊疗策略的影响  

Impact of neo-adjuvant immunotherapy on the surgical treatment strategy for non-small cell lung cancer

作　　者：张哲铭 李文雅[1] ZHANG Zheming;LI Wenya(Department of Thoracic Surgery,the First Hospital Affiliated to China Medical University,Liaoning Shenyang 110001,China;The First Clinical College,China Medical University,Liaoning Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院胸外科,辽宁沈阳110001 [2]中国医科大学第一临床学院,辽宁沈阳110001

出　　处：《现代肿瘤医学》2024年第23期4548-4554,共7页Journal of Modern Oncology

基　　金：2023年辽宁省自然科学基金项目(编号:2023-MS-159)。

摘　　要：肺癌是人类常见的癌症之一,其中以非小细胞肺癌(non-small cell lung cancer,NSCLC)最为常见。近年来,新辅助免疫治疗逐渐兴起,并被广泛应用于肺癌的诊疗中。该文现就新辅助免疫治疗联合其它新辅助治疗在非小细胞肺癌应用方面的可行性和安全性进行综述,希望能为未来相关诊疗策略的制定提供参考。Lung cancer is one of the most common cancers in human,of which non-small cell lung cancer(NSCLC)is the most common.In recent years,neo-adjuvant immunotherapy has been gradually emerged and has been widely used in the treatment of lung cancer.In this paper,the feasibility and safety of neo-adjuvant immunotherapy combined with other neo-adjuvant therapies for non-small cell lung cancer are reviewed,and we hope that it can provide a reference for the development of relevant diagnostic and therapeutic strategies in the future.

关 键 词：肺癌 新辅助治疗 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]